Author:
Feng Rundong,Patil Suryaji,Zhao Xin,Miao Zhiping,Qian Airong
Abstract
RNA therapeutics involve the use of coding RNA such as mRNA as well as non-coding RNAs such as small interfering RNAs (siRNA), antisense oligonucleotides (ASO) to target mRNA, aptamers, ribozymes, and clustered regularly interspaced short palindromic repeats-CRISPR-associated (CRISPR/Cas) endonuclease to target proteins and DNA. Due to their diverse targeting ability and research in RNA modification and delivery systems, RNA-based formulations have emerged as suitable treatment options for many diseases. Therefore, in this article, we have summarized different RNA therapeutics, their targeting strategies, and clinical progress for various diseases as well as limitations; so that it might help researchers formulate new and advanced RNA therapeutics for various diseases. Additionally, U.S. Food and Drug Administration (USFDA)-approved RNA-based therapeutics have also been discussed.
Subject
Biochemistry, Genetics and Molecular Biology (miscellaneous),Molecular Biology,Biochemistry
Reference143 articles.
1. RNAi Therapeutics: Principles, Prospects and Challenges;Aagaard;Adv. Drug Deliv. Rev.,2007
2. Aptamers: A Review of Their Chemical Properties and Modifications for Therapeutic Application;Adachi;Molecules,2019
3. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis;Adams;N. Engl. J. Med.,2018
4. Safety and Immunogenicity of a mRNA Rabies Vaccine in Healthy Adults: An Open-Label, Non-randomised, Prospective, First-In-Human Phase 1 Clinical Trial;Alberer;The Lancet,2017
5. SLN124, a Galnac-siRNA Conjugate Targeting TMPRSS6, for the Treatment of Iron Overload and Ineffective Erythropoiesis Such as in Beta-Thalassemia;Altamura;Blood,2018
Cited by
46 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献